natgillin/translations-raw huggingface dataset:
Women of child bearing should be advised to use effective contraception to avoid pregnancy while they are receiving TMZ.
Ženskam v rodni dobi je treba svetovati, naj se med zdravljenjem s TMZ uporabljajo učinkovito kontracepcijo, da preprečijo zanositev.
Women of child- bearing potential should be advised to avoid becoming pregnant.
Ženskam v rodni dobi je treba naročiti, naj pazijo, da ne bodo zanosile.
Women of child-bearing age must use an effective method of birth control while using Panretin, and for one month after finishing treatment.
Plodne ženske si morajo tako v času uporabe kot tudi en mesec po prenehanju uporabe zdravila Panretin gel zagotoviti učinkovito kontracepcijsko sredstvo.
Women of child-bearing age should avoid contact with, or wear disposable gloves, when administering the product.
Ženske v rodni dobi bi se morale izogibati stiku z zdravilom ali pri dajanju zdravila nositi rokavice za enkratno uporabo.
Women of child-bearing potential
Ţenske v rodni dobi
Women of child-bearing potential have to take appropriate contraceptive measures.
Ženske v rodni dobi morajo med zdravljenjem uporabljati ustrezno kontracepcijo.
Women of child-bearing potential have to take appropriate contraceptive measures.
Ženske v rodni dobi morajo med zdravljenjem uporabljati učinkovito kontracepcijo.
Women of child-bearing potential must always use effective contraception during treatment.
Ženske v rodni dobi morajo med zdravljenjem vedno uporabljati učinkovito kontracepcijo.
Women of child-bearing potential must be advised to avoid pregnancy while they or their male partner are receiving Caelyx and in the six months following discontinuation of Caelyx therapy (see section 5.3).
Ženskam v rodni dobi morate svetovati, naj ne zanosijo, medtem ko same ali njihov partner prejemajo zdravilo Caelyx in še šest mesecev po prenehanju zdravljenja z njim (glejte poglavje 5.3).
Women of child-bearing potential must use adequate contraception during treatment with zonisamide and for one month after discontinuation (see section 4.6).
Ženske v rodni dobi morajo med zdravljenjem ter vsaj še mesec dni po končanem zdravljenju z zonisamidom uporabljati ustrezno kontracepcijo (glejte poglavje 4.6).
Women of child-bearing potential should avoid becoming pregnant during treatment with rivaroxaban.
Ženske v rodni dobi naj se med zdravljenjem z zdravilom Xarelto izogibajo zanositvi.
Women of child-bearing potential should be advised to use an adequate method of contraception during the course of treatment;
ženskam v rodni dobi je treba svetovati, naj med zdravljenjem uporabljajo primerno kontracepcijsko metodo;
Women of child-bearing potential should inform their surgeon of the possibility of pregnancy before they are administered this medicine.
Ženske v rodni dobi morajo pred uporabo tega zdravila obvestiti zdravnika o mogoči zanositvi.
Women of child-bearing potential should inform their surgeon of the possibility of pregnancy before undergoing treatment with Osigraft.
Ženske v rodni dobi morajo pred začetkom zdravljenja z zdravilom Osigraft obvestiti zdravnika o možni zanositvi.
Women of child-bearing potential should inform their surgeon of the possibility of pregnancy prior to treatment with the medicine.
Ženske v rodni dobi morajo pred zdravljenjem z zdravilom obvestiti zdravnika o možni zanositvi.
Women of child-bearing potential should take appropriate contraceptive measures.
Ženske v rodni dobi morajo med zdravljenjem uporabljati kontracepcijo.
Women of child-bearing potential should take appropriate contraceptive measures.
Ženske v rodni dobi morajo med zdravljenjem uporabljati ustrezno kontracepcijsko metodo.
Women of child-bearing potential should take appropriate contraceptive measures.
Ženske v rodni dobi morajo uporabljati učinkovito kontracepcijo.
Women of child-bearing potential should take the necessary precautions to avoid pregnancy for 1 month following vaccination.
Ženske v rodni dobi morajo 1 mesec po cepljenju poskrbeti za ustrezno zaščito pred zanositvijo.
Women of child-bearing potential should use adequate birth-control measures during treatment with anagrelide.
Ženske v rodni dobi morajo uporabljati učinkovito kontracepcijo med zdravljenjem z anagrelidom.
Women of child-bearing potential should use effective contraception during treatment with ORENCIA and up to 14 weeks after the last dose of abatacept treatment.
Ženske v rodni dobi morajo uporabljati učinkovito kontracepcijo med zdravljenjem z zdravilom ORENCIA in do 14 tednov po prejemu zadnjega odmerka abatacepta.
Women of child-bearing potential using hormonal contraceptives are advised to use an additional safe and effective contraceptive method (see section 4.4 and 4.6).
Ženskam v rodni dobi, ki uporabljajo hormonska kontracepcijska sredstva, svetujemo, naj dodatno uporabljajo še eno od varnih in učinkovitih kontracepcijskih metod (glejte poglavji 4.4 in 4.6).
Women of child-bearing potential/Contraception
Ženske v rodni dobi / kontracepcija
Women of child-bearing potential/Contraception in females
Ženske v rodni dobi/kontracepcija pri ženskah
Women of child-bearing potential/contraception in males and females
Ženske v rodni dobi/kontracepcija pri moških in ženskah
Women of childbearing age being treated with Iclusig should avoid becoming pregnant.
Ženske v rodni dobi, ki se zdravijo z zdravilom Iclusig, ne smejo zanositi.
Women of childbearing age being treated with Iclusig should be advised not to become pregnant and men being treated with Iclusig should be advised not to father a child during treatment.
Ženskam v rodni dobi, ki se zdravijo z zdravilom Iclusig, je treba svetovati, da naj v času zdravljenja z zdravilom Iclusig ne zanosijo, moškim pa, da naj v času zdravljenja z zdravilom Iclusig ne zaplodijo otroka.
Women of childbearing age receiving hydroxycarbamide should be advised to avoid becoming pregnant, and to inform the treating physician immediately should this occur.
Ženskam v rodni dobi je treba svetovati, da naj med zdravljenjem s hidroksikarbamidom ustrezno poskrbijo za preprečevanje zanositve, in da naj takoj obvestijo lečečega zdravnika, če zanosijo.
Women of childbearing age should be tested for pregnancy before beginning therapy, and during therapy utilise some form of pregnancy contraceptive.
Pri ženskah v rodni dobi je treba pred začetkom zdravljenja opraviti preizkus nosečnosti, med zdravljenjem pa morajo uporabljati eno izmed oblik kontracepcije.
Women of childbearing potential
IMETNIK DOVOLJENJA ZA PROMET Z ZDRAVILOM
Women of childbearing potential (WCBP)
Ženske v rodni dobi
Women of childbearing potential / Contraception
Ženske v rodnem obdobju/Kontracepcija
Women of childbearing potential / Contraception in females
Ženske v rodni dobi/kontracepcija pri ženskah
Women of childbearing potential / Contraception in males and females
Ženske v rodni dobi/Kontracepcija pri moških in ženskah
Women of childbearing potential / contraception in males and females
Ženske v rodni dobi/uporaba kontracepcije pri moških in ženskah
Women of childbearing potential /contraception:
Kardiotoksičnost
Women of childbearing potential and men must use effective contraception during and up to 3 months after treatment.
Ženske v rodni dobi in moški morajo uporabljati zanesljivo kontracepcijo med zdravljenjem in do 3 mesece po zdravljenju.
Women of childbearing potential and their partners should be advised to avoid pregnancies.
Ženskam v rodni dobi in njihovim partnerjem je treba svetovati, naj se izognejo nosečnosti.
Women of childbearing potential are strongly recommended to use adequate contraception to prevent pregnancy and continue its use for at least five months after the last Humira treatment.
Ženske v rodni dobi morajo za preprečitev nosečnosti uporabljati ustrezno kontracepcijsko zaščito in z njo nadaljevati vsaj še pet mesecev po zadnjem zdravljenju z zdravilom Humira.
Women of childbearing potential are strongly recommended to use adequate contraception to prevent pregnancy and to continue its use for at least 18 weeks after the last treatment with Entyvio.
Pri ženskah v rodni dobi močno priporočamo uporabo učinkovite kontracepcije za preprečitev nosečnosti med zdravljenjem z zdravilom Entyvio in še vsaj 18 tednov po prejemu zadnjega odmerka.
Women of childbearing potential have to use effective contraception and avoid becoming pregnant while being treated with asparaginase-containing chemotherapy.
Ženske v rodni dobi morajo uporabljati učinkovito kontracepcijo in ne smejo zanositi, ko se zdravijo s kemoterapijo, katere del je asparaginaza.
Women of childbearing potential have to use effective contraception during and after treatment.
Ženske v rodni dobi morajo med zdravljenjem in po njem uporabljati učinkovito kontracepcijo.
Women of childbearing potential have to use effective contraception during and for 12 months after the last ofatumumab treatment.
Ženske v rodni dobi morajo med zdravljenjem z ofatumumabom in še 12 mesecev po zadnjem odmerku tega zdravila uporabljati učinkovito kontracepcijo.
Women of childbearing potential have to use effective contraception during and up to 2 years after treatment (see “ waiting period” below) or up to 11 days after treatment (see abbreviated “ washout period” below).
Ženske v rodni dobi morajo uporabljati učinkovito kontracepcijo med zdravljenjem in do dve leti po prenehanju zdravljenja (glejte tudi “čakalno obdobje” spodaj), ali do 11 dni po prenehanju zdravljenja (glejte skrajšani “postopek izpiranja” spodaj).
Women of childbearing potential have to use effective contraception during treatment and for at least 3 months after the last intravitreal injection of aflibercept (see section 4.6).
Ženske v rodni dobi morajo med zdravljenjem in še vsaj 3 mesece po zadnji intravitrealni injekciji aflibercepta uporabljati učinkovito kontracepcijo (glejte poglavje 4.6).
Women of childbearing potential have to use effective contraception during treatment and for at least 6 months after treatment.
Ženske v rodni dobi morajo med zdravljenjem in vsaj še 6 mesecev po zdravljenju uporabljati učinkovito kontracepcijsko zaščito.
Women of childbearing potential have to use effective contraception during treatment and for at least three further months after the last injection of Eylea.
Ženske v rodni dobi morajo med zdravljenjem in še vsaj tri mesece po zadnji injekciji zdravila Eylea uporabljati učinkovito kontracepcijo.
Women of childbearing potential have to use effective contraception during treatment and up to 5 months after treatment.
Ženske v rodni dobi morajo uporabljati učinkovito kontracepcijo med zdravljenjem in do 5 mesecev po njem.
Women of childbearing potential have to use effective contraception during treatment with Zonegran and for one month after discontinuation (see section 4.6).
Ženske v rodni dobi morajo uporabljati učinkovito kontracepcijo med zdravljenjem ter vsaj še mesec dni po končanem zdravljenju z zdravilom Zonegran (glejte poglavje 4.6).
Women of childbearing potential have to use effective contraception during treatment with Zonegran, and for one month after discontinuation.
Ženske v rodni dobi morajo uporabljati učinkovito kontracepcijo med zdravljenjem z zdravilom Zonegran in en mesec po njem.
Women of childbearing potential have to use highly effective contraception during treatment with Tasigna and for up to two weeks after ending treatment.
Ženske v rodni dobi morajo med zdravljenjem z zdravilom Tasigna in še dva tedna po zaključku zdravljenja uporabljati zelo učinkovito kontracepcijo.
Women of childbearing potential must be advised not to get pregnant during therapy.
Ženskam v rodni dobi je treba svetovati, da med zdravljenjem ne smejo zanositi.
Women of childbearing potential must be advised to avoid pregnancy due to the clastogenic and teratogenic properties of the medicinal product.
Ženskam v rodni dobi je treba svetovati, naj ne zanosijozaradi klastogenih in teratogenih lastnosti zdravila.
Women of childbearing potential must be advised to avoid pregnancy while on cabozantinib.
Ženskam v rodni dobi je treba svetovati, da v času zdravljenja s kabozantinibom ne smejo zanositi.
Women of childbearing potential must be advised to use reliable barrier contraception methods in accordance with the guidelines for immunosuppressants for a minimum of 12 months from the start of therapy (9 months following cessation of immunosuppressants).
Ženskam v rodni dobi je treba svetovati, naj uporabljajo zanesljive pregradne kontracepcijske metode skladno s smernicami za imunosupresivna sredstva vsaj 12 mesecev od začetka zdravljenja (9 mesecev po ukinitvi imunosupresivnih sredstev).
Women of childbearing potential must be informed that regorafenib may cause foetal harm.
Ženske v rodni dobi je treba obvestiti, da lahko regorafenib škoduje plodu.
Women of childbearing potential must not take AUBAGIO without using reliable contraceptive measures.
Ženske v rodni dobi ne smejo jemati zdravila AUBAGIO brez uporabe zanesljive kontracepcije.
Women of childbearing potential must not take Leflunomide Winthrop without using reliable contraceptive measures.
Ženske v rodni dobi ne smejo jemati zdravila Leflunomid Winthrop, če ne uporabljajo zanesljive kontracepcijske zaščite.
Women of childbearing potential must not take Repso without using reliable contraceptive measures, and they must use reliable contraceptive measures up to 2 years after treatment.
Ženske v rodni dobi ne smejo jemati zdravila Repso, če ne uporabljajo zanesljive kontracepcijske zaščite in morajouporabljati zanesljivo kontracepcijsko zaščito do 2 leti po zdravljenju.
Women of childbearing potential must use a highly effective method of contraception (e.g. oral, injected, or implanted non-oestrogen-containing hormonal method of birth control, progesterone-based contraceptives, hysterectomy, tubal ligation, complete abstinence, barrier methods, intrauterine device [IUD], and/or female/male sterilisation) while receiving everolimus, and for up to 8 weeks after ending treatment.
Ženske v rodni dobi morajo v času jemanja everolimusa in do 8 tednov po zaključku zdravljenja z njim uporabljati zelo učinkovito kontracepcijsko metodo (kot so peroralne, injekcijske ali implantacijske hormonske metode za nadzor rojstev brez estrogenov, kontraceptivi, ki temeljijo na progesteronu, histerektomija, podvezovanje jajcevodov, popolna abstinenca, metode z uporabo fizične pregrade, maternični vložek [IUD] in/ali sterilizacija ženske ali moškega).
Women of childbearing potential must use adequate contraception during treatment with zonisamide, and for one month after discontinuation.
Ženske v rodni dobi morajo med zdravljenjem z zonisamidom in en mesec po zaključenem zdravljenju uporabljati ustrezno kontracepcijo.
Women of childbearing potential must use adequate contraception to prevent pregnancy and continue its use for at least 6 months after the last Flixabi treatment.
Ženske v rodni dobi morajo za preprečevanje nosečnosti uporabljati učinkovito kontracepcijo in z njo nadaljevati še najmanj 6 mesecev po zaključku zdravljenja z zdravilom Flixabi.
Women of childbearing potential must use adequate contraception to prevent pregnancy and continue its use for at least 6 months after the last Inflectra treatment.
Ženske v rodni dobi morajo za preprečevanje nosečnosti uporabljati ustrezno kontracepcijo in z njo nadaljevati še najmanj 6 mesecev po zaključku zdravljenja z zdravilom Inflectra.
Women of childbearing potential must use adequate contraception to prevent pregnancy and continue its use for at least 6 months after the last Remicade treatment.
Ženske v rodni dobi morajo za preprečevanje nosečnosti uporabljati ustrezno kontracepcijo in z njo nadaljevati še najmanj 6 mesecev po zaključku zdravljenja z zdravilom Remicade.
Women of childbearing potential must use adequate contraception to prevent pregnancy and continue its use for at least 6 months after the last Remsima treatment.
Ženske v rodni dobi morajo za preprečevanje nosečnosti uporabljati ustrezno kontracepcijo in z njo nadaljevati še najmanj 6 mesecev po zaključku zdravljenja z zdravilom Remsima.
Women of childbearing potential must use adequate contraception while using Cimzia and for at least 5 months after the last Cimzia treatment.
Ženske v rodni dobi morajo med zdravljenjem z zdravilom Cimzia in vsaj 5 mesecev po zadnjem odmerku zdravila uporabljati primerno obliko kontracepcije.
Women of childbearing potential must use contraceptive measures during treatment and must inform their doctor immediately if they become pregnant (see section 4.3).
Ženske v rodni dobi morajo med zdravljenjem uporabljati kontracepcijo in nemudoma obvestiti zdravnika, če zanosijo (glejte poglavje 4.3).
Women of childbearing potential must use effective contraception during and up to 3 months after treatment.
Ženske v rodni dobi morajo uporabljati učinkovito kontracepcijo med zdravljenjem in do 3 mesece po končanem zdravljenju.
Women of childbearing potential must use effective contraception during and up to 3 months after treatment.
Ženske v rodni dobi morajo uporabljati učinkovito kontracepcijsko metodo med zdravljenjem in še do 3 mesece po njegovem zaključku.
Women of childbearing potential must use effective contraception during Benlysta treatment and for at least 4 months after the last treatment.
Ženske v rodni dobi morajo med zdravljenjem z zdravilom Benlysta in vsaj še 4 mesece po koncu zdravljenja uporabljati učinkovito kontracepcijsko zaščito.
Women of childbearing potential must use effective contraception during therapy and for 1 month after receiving the last dose of Lynparza.
Ženske v rodni dobi morajo med zdravljenjem z zdravilom Lynparza in še en mesec po prejetju zadnjega odmerka uporabljati učinkovito kontracepcijo.
Women of childbearing potential must use effective contraception during therapy and up to one month after treatment with this medicinal product.
Ženske v rodni dobi morajo uporabljati učinkovito kontracepcijo med zdravljenjem in še do en mesec po njem.
Women of childbearing potential must use effective contraception during treatment and 3 months thereafter, and immediately inform the treating physician if a pregnancy occurs (see section 5.3).
Ženske v rodni dobi morajo med zdravljenjem in še 3 mesece po njem uporabljati učinkovito zaščito pred zanositvijo ter nemudoma obvestiti zdravnika, če nastopi nosečnost (glejte poglavje 5.3).
Women of childbearing potential must use effective contraception during treatment and 3 months thereafter, and immediately inform the treating physician if a pregnancy occurs (see section 5.3).
Ženske v rodni dobi naj med zdravljenjem in še 3 mesece po njem uporabljajo učinkovito zaščito pred zanositvijo ter nemudoma obvestijo zdravnika, če nastopi nosečnost (glejte poglavje 5.3).
Women of childbearing potential must use effective contraception during treatment with pemetrexed.
Ženske v rodni dobi morajo uporabljati učinkovito kontracepcijo med zdravljenjem s pemetreksedom.
Women of childbearing potential must use effective contraceptive measures and avoid becoming pregnant while being treated with Dacogen.
Ženske v rodni dobi morajo v času zdravljenja z zdravilom Dacogen uporabljati učinkovito kontracepcijo in paziti, da ne bi zanosile.
Women of childbearing potential must use effective methods of contraception during therapy and for 4 weeks following discontinuation of dabrafenib and 4 months following the last dose of trametinib when given in combination with dabrafenib.
Ženske v rodni dobi morajo uporabljati učinkovito kontracepcijo med zdravljenjem in še 4 tedne po prenehanju zdravljenja z dabrafenibom in še 4 mesece po zadnjem odmerku trametiniba, če ga uporabljajo v kombinaciji z dabrafenibom.
Women of childbearing potential must use one effective method of contraception for 4 weeks before therapy, during therapy, and during 4 weeks after thalidomide therapy (see section 4.4).
Ženske v rodni dobi morajo uporabljati zanesljivo metodo kontracepcije 4 tedne pred terapijo, med terapijo ter 4 tedne po terapiji s talidomidom (glejte poglavje 4.4).
Women of childbearing potential must use one effective method of contraception for 4 weeks before therapy, during therapy, and during 4 weeks after thalidomide therapy and even in case of dose interruption unless the patient commits to absolute and continuous abstinence confirmed on a monthly basis.
Ženske v rodni dobi morajo uporabljati zanesljivo metodo kontracepcije 4 tedne pred terapijo, med terapijo ter 4 tedne po terapiji s talidomidom in celo v primeru prekinitev odmerjanja, razen če se bolnica zaveže k popolni in neprekinjeni spolni vzdržnosti, ki se potrjuje vsak mesec.
Women of childbearing potential must use one effective method of contraception for 4 weeks before therapy, during therapy, and until 4 weeks after pomalidomide therapy and even in case of dose interruption unless the patient commits to absolute and continuous abstinence confirmed on a monthly basis.
Ženske v rodni dobi morajo 4 tedne pred začetkom zdravljenja, med zdravljenjem in 4 tedne po zdravljenju s pomalidomidom in celo med morebitnimi prekinitvami odmerjanja uporabljati eno zanesljivo kontracepcijsko metodo, razen če se zavežejo popolni in neprekinjeni abstinenci, ki se potrjuje vsak mesec.
Women of childbearing potential must use reliable contraception while taking tedizolid phosphate.
Ženske v rodni dobi morajo v obdobju jemanja tedizolid fosfata uporabljati zanesljivo kontracepcijo.
Women of childbearing potential not using contraceptive measures (see section 4.6).
Ženske v rodni dobi, ki ne uporabljajo kontracepcije (glejte poglavji 4.6).
Women of childbearing potential should avoid becoming pregnant during treatment with edoxaban.
Ženske v rodni dobi med zdravljenjem z edoksabanom ne smejo zanositi.
Women of childbearing potential should avoid pregnancy during treatment with dabigatran etexilate.
Ženske v rodni dobi ne smejo zanositi med zdravljenjem z dabigatran eteksilatom.
Women of childbearing potential should be advised not to become pregnant during safinamide therapy.
Ženskam v rodni dobi je treba svetovati, naj se izogibajo zanositvi med zdravljenjem s safinamidom.
Women of childbearing potential should be advised to avoid becoming pregnant while on Cyramza and should be informed of the potential hazard to the pregnancy and foetus.
Ženskam v rodni dobi je treba svetovati, naj se izognejo zanositvi med zdravljenjem z zdravilom Cyramza in jih je treba seznaniti z možnim tveganjem za nosečnost in plod.
Women of childbearing potential should be advised to avoid becoming pregnant while on necitumumab and should be informed of the potential hazard to the pregnancy and foetus.
Ženskam v rodni dobi je treba svetovati, naj se izognejo zanositvi med zdravljenjem z necitumumabom in jih je treba seznaniti z možnim tveganjem za nosečnost in plod.
Women of childbearing potential should be advised to avoid becoming pregnant while on ZALTRAP, and should be informed of the potential hazard to the foetus.
Ženskam v rodni dobi je treba svetovati, naj med zdravljenjem z zdravilom ZALTRAP ne zanosijo, in jih je treba obvestiti o možnih nevarnostih za plod.
Women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment with capecitabine.
Ženskam v rodni dobi je treba svetovati naj ne zanosijo, medtem ko se zdravijo s kapecitabinom.
Women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment with this medicinal product.
Ženskam v rodni dobi je treba svetovati, da naj med zdravljenjem s tem zdravilom ustrezno poskrbijo za preprečevanje zanositve.
Women of childbearing potential should be advised to use adequate contraception and avoid becoming pregnant while receiving treatment with Tyverb.
Ženskam v rodni dobi je treba svetovati, da naj za preprečitev nosečnosti med zdravljenjem z zdravilom Tyverb uporabljajo ustrezno kontracepcijsko metodo.
Women of childbearing potential should be advised to use adequate contraception during the treatment and at least 2 weeks after treatment and avoid becoming pregnant while receiving treatment with pazopanib.
Ženskam v rodni dobi je treba svetovati uporabo primerne metode kontracepcije med zdravljenjem in še najmanj 2 tedna po zaključku zdravljenja in pojasniti, da med zdravljenjem s pazopanibom ne smejo zanositi.